Dupixent (dupilumab) is given by injection every two weeks. It was approved to treat patients with nasal polyps and chronic rhinosinusitis — defined as a prolonged inflammation of the sinuses and nasal cavity, the FDA said.
Source: Medical News
Dupixent (dupilumab) is given by injection every two weeks. It was approved to treat patients with nasal polyps and chronic rhinosinusitis — defined as a prolonged inflammation of the sinuses and nasal cavity, the FDA said.
Source: Medical News